ClinicalTrials.gg
WithdrawnNCT04930770VAX-TRESUpdated Jun 22, 2025

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination

A Phase 2 interventional study of MRNA-1273 in Covid19, sponsored by Maria Joyera Rodríguez. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Maria Joyera Rodríguez · Phase 2, Interventional, and Prevention

How we know

Why this study was withdrawn
No candidates for the trial (all patients have received the third dose of the vaccine)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
34th of 36
0 · median 499
Started
2021
with 20 others
Phase 2
7 of 36
none open now
Registered
18th of 36
by date
Lead sponsor
1 of 36
Maria Joyera Rodríguez

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 34th largest by enrollment, is one of 21 that started in 2021, is one of 7 in phase 2, and was the 18th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full standard (two-dose) regimen.

03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • vaccine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years;
  2. Male or female sex;
  3. Renal transplant with stable renal function in the last 2 months prior to study inclusion.
  4. Had received a full schedule of vaccination for SARS-CoV-2 with mRNA1273 vaccine (Moderna) and remained seronegative at 2 weeks after the second dose.
  5. Patient giving written .

Exclusion criteria

Exclusion Criteria:

  1. Renal transplantation \< 3 months;
  2. Pregnancy or lactation status;
  3. Rejection treated within the last 6 months;
  4. Presence of humoral immunity to SARS-CoV-2 defined as the presence of specific IgM/IgG.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Renal/renopancreatic transplant's patients with a verified seronegativity

    Drug: MRNA-1273

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with development of cellular and humoral immunity against SARS-CoV-2

    the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full standard (two-dose) regimen

    Time frame: 2 weeks

Secondary outcomes

  1. Number of patients with development of cellular and humoral immunity against SARS-CoV-2

    development of cellular and humoral immunity against SARS-CoV-2 after 4 months of administration of a third dose of mRNA-1273 vaccine (Moderna).

    Time frame: 4 months

  2. patient characteristics associated with biological non-response to vaccination

    Analysis of baseline factors associated with biological non-response to vaccination, including demographics, comorbidities, and transplant-associated factors. The following items will be reviewed: age, sex, diabetes, type of transplant (kidney-pancreas versus kidney), treatment with anti-thymocyte globulins (ATG) during the last year, lymphopenia defined as \< 1000/mm3, time from transplantation \< 1 year, eGFR (CKD-EPI), baseline immunosuppression, according to individual drug or the combination received by the patient, type of donor, BMI, ethnicity and blood type.

    Time frame: 4 months

  3. Incidence of Treatment-Emergent Adverse Events

    Percentage of patients with mild and/or severe adverse events after administration of the third dose (safety and tolerability). Number of participants with treatment-related adverse events as assessed by the WHO toxicity scale.

    Time frame: 4 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2021; primary completion for Dec 2021, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jun 18, 2021
StartEst.
Sep 2021
Primary completionEst.
Dec 1, 2021
CompletionEst.
Mar 1, 2022
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04930770
Lead sponsor
Maria Joyera Rodríguez
Responsible party
Maria Joyera Rodríguez (Clinical Research Manager, Fundacion Clinic per a la Recerca Biomédica) — Sponsor-investigator
First posted
Jun 18, 2021
Start date
Sep 2021 (estimated)
Primary completion
Dec 1, 2021 (estimated)
Completion
Mar 1, 2022 (estimated)
Last update
Jun 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273

Start the discussion